Venous thromboembolism (VTE) has long been recognized as one of the earliest clinical manifestations of an underlying malignancy. More than 160 years after Trousseau first recognized the association between migratory thrombophlebitis and occult cancer, the link between thrombosis and malignancy remains one of the most compelling examples of the intricate interplay between haemostasis and cancer biology. Contemporary evidence indicates that approximately 5% of patients with apparently unprovoked VTE are diagnosed with cancer during the year following the thrombotic event, with most diagnoses occurring within the first six months [1].
